Skip to main content

Table 5 Most common toxicities in studies of PARPi monotherapy in breast cancer patients

From: PARP inhibitors in the management of breast cancer: current data and future prospects

Compound

Adverse event (range of occurrence across studies)

Grade 1–2

Grade 3–4

Olaparib [5–7, 34, 134]

Nausea (32–58 %)

 

Fatigue (30–50 %)

 

Vomiting (11–34 %)

Nausea (4–15 %)

Anorexia (12–27 %)

Fatigue (5–15 %)

Anemia (5–25 %)

Anemia (11–15 %)

Headache (22 %)

Vomiting (4–11 %)

Diarrhea (11–18 %)

Thrombocytopenia (3 %)

Taste alteration (13 %)

 

Veliparib [135]

Dizziness (7 %)

–

Nausea (7 %)

Dysgeusia (7 %)

Talazoparib [32]

Fatigue (26 %)

 

Nausea (26 %)

 

Alopecia (grade 1 only, 26 %)

Neutropenia (8 %)

Anemia (13 %)

Thrombocytopenia (8 %)

Neutropenia (10 %)

Anemia (5 %)

Flatulence (10 %)

 

Thrombocytopenia (3 %)

Niraparib [31]

Anemia (48 %)

 

Nausea (42 %)

 

Thrombocytopenia (35 %)

Thrombocytopenia (15 %)

Fatigue (34 %)

Anemia (10 %)

Anorexia (25 %)

Fatigue (8 %)

Neutropenia (24 %)

Neutropenia (4 %)

Constipation (23 %)

 

Vomiting (19 %)

 

Insomnia (10 %)

 

Rucaparib [33]a

Fatigue (30–39 %)

Nausea (27–30 %)

Diarrhea (13–20 %)

Vomiting (23 %)

Dizziness (17 %)

Anorexia (11 %)

  1. Grading according to Common Toxicology Criteria for Adverse Event
  2. aGrade of reported adverse events not specified